--- title: "ESTA Founder Sells $7.9M on Earnings Day — Here's Why that's Not the Story" type: "News" locale: "en" url: "https://longbridge.com/en/news/286021443.md" description: "On May 6, 2026, Juan José Chacón Quirós, founder of Establishment Labs, sold 105,000 shares for approximately $7.92 million, representing 9.74% of his total holdings. This sale was part of a pre-scheduled 10b5-1 plan and coincided with the company's Q1 earnings release, which showed a 13.3% revenue increase. Despite the sale, Chacón Quirós retains nearly 973,000 shares. Investors should focus on the company's growth potential and upcoming reconstruction approval rather than the insider sale." datetime: "2026-05-12T01:55:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286021443.md) - [en](https://longbridge.com/en/news/286021443.md) - [zh-HK](https://longbridge.com/zh-HK/news/286021443.md) --- # ESTA Founder Sells $7.9M on Earnings Day — Here's Why that's Not the Story ## Key Points - 105,000 shares were indirectly sold on May 6, 2026, generating a transaction value of ~$7.92 million at a weighted average price around $75.42 per share. - This transaction represented 9.74% of total holdings for the reporting person, reducing indirect shares to 927,504 and direct shares remaining at 45,193. - All shares disposed in this filing were held indirectly. - 10 stocks we like better than Establishment Labs › On May 6, 2026, Founder and former CEO Juan José Chacón Quirós, now serving as a director and paid consultant, reported the indirect sale of 105,000 shares of **Establishment Labs Holdings Inc.** (NASDAQ:ESTA) for a total of approximately $7.92 million, according to a SEC Form 4 filing. ## Transaction summary Metric Value Shares sold (indirect) 105,000 Transaction value $7.9 million Post-transaction shares (direct) 45,193 Post-transaction shares (indirect) 927,504 Post-transaction value (direct ownership) ~$3.37 million _Transaction value based on SEC Form 4 weighted average purchase price ($75.42); post-transaction value based on May 6, 2026 market close price ($74.54)._ ## Key questions - **What portion of the insider’s total position was impacted by this sale?** This sale represented 9.74% of Chacon Quiros’s combined direct and indirect holdings, or 10.17% of the indirect position managed through Sariel Group Ltd, with no direct shares traded in this event. - **What is the ownership structure and how does the indirect nature of this sale affect control?** The 105,000 shares were held indirectly through Sariel Group Ltd; although Chacon Quiros has voting and dispositive power, he disclaims beneficial ownership except for his pecuniary interest, which is typical for entity-structured insider holdings. - **How does this transaction compare to the insider’s historical trading cadence and capacity?** The 105,000-share sale is the largest single sale by Chacon Quiros to date. With a large block of direct shares transferred into Sariel Group in March 2026, the pool available for future direct-share transactions is considerably smaller than it was a year ago, meaning future sale sizes are increasingly constrained by available capacity rather than discretionary moderation. - **What does the conclusion of the 10b5-1 plan mean for future trading activity?** With all shares subject to the December 2025 10b5-1 plan now sold, any future activity would require adoption of a new plan or be subject to open-market trading windows, potentially reducing the predictability of sale cadence going forward. ## Company overview Metric Value Price (as of market close 2026-05-09) $71.77 Market capitalization $2.11 billion Revenue (TTM) $229.58 million 1-year price change 111.6% \* 1-year performance calculated using May 9th, 2026 as the reference date. ## Company snapshot - Offers silicone gel-filled breast implants (Motiva Implants, Motiva Ergonomix, Motiva Ergonomix2), Motiva Flora Tissue Expander, and distributes Puregraft products for autologous adipose tissue harvesting. - Generates revenue primarily through the manufacturing and direct or distributor-based sales of medical devices for aesthetic and reconstructive plastic surgery. - Serves plastic surgeons and healthcare providers in Europe, Latin America, the Asia-Pacific, and other international markets. Establishment Labs Holdings Inc. is a global medical technology company specializing in advanced breast implant solutions and related surgical devices. The company leverages proprietary product designs and a diversified international distribution network to address the needs of plastic and reconstructive surgeons. Its focus on innovation and international market access underpins its competitive position in the medical devices sector. ## What this transaction means for investors This sale was pre-scheduled under a 10b5-1 plan adopted in December 2025, so the timing — which landed on the same day as Q1 earnings — is coincidental, not a read on results. Chacon Quiros is the founder and former CEO who stepped down in early 2025 and now serves as a paid consultant and board director, with nearly 973,000 shares still held between his entity and direct stake. The more relevant numbers are in the Q1 release: US revenue hit $19.6 million, up 13.3% from Q4 2025, and the company posted its third consecutive quarter of positive adjusted EBITDA. Full-year guidance was raised and management is targeting free cash flow positive in the second half of 2026. A reconstruction approval application is pending on top of the existing augmentation clearance. If you're evaluating ESTA, the question isn't what the founder did with a pre-scheduled slice of his position — it's whether the US ramp sustains and whether the reconstruction approval adds a second growth leg. Those are the variables worth tracking before making a position decision. ## Should you buy stock in Establishment Labs right now? Before you buy stock in Establishment Labs, consider this: The _Motley Fool Stock Advisor_ analyst team just identified what they believe are the **10 best stocks** for investors to buy now… and Establishment Labs wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when **Netflix** made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, **you’d have $471,827**!\* Or when **Nvidia** made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, **you’d have $1,319,291**!\* Now, it’s worth noting _Stock Advisor’s_ total average return is 986% — a market-crushing outperformance compared to 207% for the S&P 500. **Don't miss the latest top 10 list, available with _Stock Advisor_, and join an investing community built by individual investors for individual investors.** See the 10 stocks » _\*Stock Advisor returns as of May 11, 2026._ _Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy._ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [ESTA.US](https://longbridge.com/en/quote/ESTA.US.md) ## Related News & Research - [Monarch Alternative Capital sells eight seniors housing properties in portfolio exit](https://longbridge.com/en/news/296240718.md) - [Sea Chairman and CEO Li Xiaodong sells Sea shares worth $2.39 million](https://longbridge.com/en/news/296088860.md) - [Global-e CEO Amir Schlachet sells 16,814 shares for $713,890.60](https://longbridge.com/en/news/295833532.md) - [Xenon Pharmaceuticals director Steven Gannon disposes of 10,000 common shares for $640,550](https://longbridge.com/en/news/295844352.md) - [Diageo announces BRL 0.32 per unit distribution for Q3 2026](https://longbridge.com/en/news/295964479.md)